人工智能驱动的程序性死亡配体1分析仪减少非小细胞肺癌肿瘤比例评分的观察者间差异并更好预测免疫治疗反应
本研究开发了基于802张非小细胞肺癌全切片图像的人工智能驱动PD-L1肿瘤比例评分分析仪原型,由3名病理学家对479张切片独立评分,并在与AI不一致时借助AI修正。AI辅助后病理学家间总体一致率从81.4%升至90.2%(P<0.001),且AI辅助修正后的TPS亚组显示免疫检查点抑制剂治疗的总生存和无进展生存风险比降低。
要点
- 无AI辅助时病理学家对TPS的一致分类率为81.4%,AI辅助后升至90.2%(P<0.001)。
- 每位病理学家与AI不一致并修正的病例数分别为91、93和107例。
- AI辅助TPS修正后,ICI治疗的总生存和无进展生存风险比在TPS亚组中降低。
核心结论
- AI驱动的TPS分析仪辅助可提高病理学家判读共识并改善治疗反应预测,提示可能实现标准化准确判读。
研究设计与样本
- 使用802张非小细胞肺癌全切片图像开发AI驱动TPS分析仪原型模型。
- 3名独立委员会认证病理学家在479张非小细胞肺癌切片的外部队列中标注PD-L1 TPS。
主要发现
- 无AI辅助时病理学家一致分类TPS的病例占81.4%。
- 病理学家与AI模型不一致的病例数分别为91、93和107例(对应每位病理学家)。
- AI辅助后病理学家间总体一致率增至90.2%(P<0.001)。
- AI辅助TPS修正后,ICI治疗的总生存和无进展生存风险比在TPS亚组中降低。
关键数值与推荐
- TPS分级阈值:<1%、1%-49%和≥50%。
- 无AI辅助时病理学家一致分类率81.4%,AI辅助后总体一致率90.2%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Manual evaluation of programmed death ligand 1 (PD-L1) tumour proportion score (TPS) by pathologists is associated with interobserver bias. OBJECTIVE: This study explored the role of artificial intelligence (AI)-powered TPS analyser in minimisation of interobserver variation and enhancement of therapeutic response prediction. METHODS: A prototype model of an AI-powered TPS analyser was developed with a total of 802 non-small cell lung cancer (NSCLC) whole-slide images. Three independent board-certified pathologists labelled PD-L1 TPS in an external cohort of 479 NSCLC slides. For cases of disagreement between each pathologist and the AI model, the pathologists were asked to revise the TPS grade (<1%, 1%-49% and ≥50%) with AI assistance. The concordance rates among the pathologists with or without AI assistance and the effect of the AI-assisted revision on clinical outcome upon immune checkpoint inhibitor (ICI) treatment were evaluated. RESULTS: Without AI assistance, pathologists concordantly classified TPS in 81.4% of the cases. They revised their initial interpretation by using the AI model for the disagreement cases between the pathologist and the AI model (N = 91, 93 and 107 for each pathologist). The overall concordance rate among the pathologists was increased to 90.2% after the AI assistance (P < 0.001). A reduction in hazard ratio for overall survival and progression-free survival upon ICI treatment was identified in the TPS subgroups after the AI-assisted TPS revision. CONCLUSION: The AI-powered TPS analyser assistance improves the pathologists' consensus of reading and prediction of the therapeutic response, raising a possibility of standardised approach for the accurate interpretation.
引用
- Choi S, Cho SI, Ma M, et al. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. Eur J Cancer. 2022. PMID: 35576849. doi:10.1016/j.ejca.2022.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。